Perennial Advisors’s Pfizer PFE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q1
Sell
-4,780
Closed -$245K 112
2022
Q4
$245K Sell
4,780
-50
-1% -$2.4K 0.08% 81
2022
Q3
$211K Hold
4,830
0.07% 80
2022
Q2
$253K Hold
4,830
0.08% 78
2022
Q1
$250K Sell
4,830
-55
-1% -$2.85K 0.07% 80
2021
Q4
$288K Buy
+4,885
New +$242K 0.08% 72
2021
Q3
Sell
-4,385
Closed -$172K 222
2021
Q2
$172K Hold
4,385
0.05% 81
2021
Q1
$159K Sell
4,385
-150
-3% -$5.33K 0.05% 82
2020
Q4
$167K Buy
+4,535
New +$166K 0.06% 79
2020
Q3
Sell
-4,865
Closed -$151K 167
2020
Q2
$151K Sell
4,865
-7,587
-61% -$258K 0.06% 78
2020
Q1
$386K Buy
12,452
+6,635
+114% +$226K 0.22% 64
2019
Q4
$216K Buy
+5,817
New +$207K 0.1% 75
2019
Q3
Sell
-5,272
Closed -$217K 76
2019
Q2
$217K Sell
5,272
-533
-9% -$21.2K 0.12% 71
2019
Q1
$234K Hold
5,805
0.13% 72
2018
Q4
$240K Hold
5,805
0.16% 66
2018
Q3
$243K Hold
5,805
0.14% 68
2018
Q2
$200K Hold
5,805
0.12% 73
2018
Q1
$195K Hold
5,805
0.12% 70
2017
Q4
$199K Buy
5,805
+396
+7% +$13.5K 0.12% 72
2017
Q3
$183K Hold
5,409
0.12% 74
2017
Q2
$172K Buy
5,409
+396
+8% +$12.5K 0.12% 73
2017
Q1
$163K Sell
5,013
-1,763
-26% -$55.6K 0.13% 73
2016
Q4
$209K Buy
+6,776
New +$207K 0.17% 72

Other funds holding PFE

Perennial Advisors's PFE Position: Q1 2023 in Review

Perennial Advisors sold out of Pfizer (PFE) in Q1 2023, closing a stake of 4,780 shares — an estimated $245K sold.

Perennial Advisors first reported a position in PFE in Q4 2016 and held it in 22 quarters. The position peaked at $386K in Q1 2020. 3,103 funds tracked by Wall St. Rank hold PFE as of Q1 2023.

  • Perennial Advisors reported no remaining Pfizer position as of Q1 2023 after selling out during the quarter.
  • Perennial Advisors sold 4,780 Pfizer shares in Q1 2023, an estimated $245K.
  • Perennial Advisors first reported a position in Pfizer in Q4 2016 and held it in 22 quarters.
  • Perennial Advisors's Pfizer position peaked at $386K in Q1 2020.
  • 3,103 funds tracked by Wall St. Rank held Pfizer as of Q1 2023.

Based on Perennial Advisors's 13F filing for Q1 2023, filed 12 May 2023.